- Tytuł:
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology December 2020 21(12):1574-1588
Czasopismo naukowe